Target Name: ANKRD65
NCBI ID: G441869
Review Report on ANKRD65 Target / Biomarker Content of Review Report on ANKRD65 Target / Biomarker
ANKRD65
Other Name(s): Ankyrin repeat domain 65, transcript variant 1 | ANR65_HUMAN | Ankyrin repeat domain-containing protein 65 | Ankyrin repeat domain-containing protein 65 (isoform 1) | ANKRD65 variant 1 | ankyrin repeat domain 65

ANKRD65: A Potential Drug Target and Biomarker

Ankyrin repeat domains (ANKRDs) are a class of non-coding RNA molecules that have been identified as potential drug targets in various diseases. ANKRD65 is a unique ANKRD that has been identified in the human gene database and has the potential to be a drug target or biomarker. In this article, we will explore the ANKRD65 molecule, its potential drug target potential, and its potential as a biomarker for various diseases.

The ANKRD65 Molecule

ANKRD65 is a non-coding RNA molecule that is approximately 190 nucleotides long. It is characterized by the presence of an ANKRD domain, which is a specific type of non-coding RNA molecule that is composed of a repeated sequence of amino acids. The ANKRD domain is responsible for the stability and stability of the RNA molecule.

The ANKRD65 molecule has four exons, which are the first four amino acids that are encoded in the RNA molecule. The first exon has a reading frame of +65 and the last exon has a reading frame of -65. The +65 reading frame is the region of the RNA molecule that contains the potential drug target.

The Potential Drug Target

The ANKRD65 molecule has been shown to have various drug target potential. One of the potential drug targets is the protein p16INK4a, which is a transcription factor that is involved in cell proliferation and has been linked to various diseases, including cancer.

The p16INK4a protein has been shown to interact with the ANKRD65 molecule and can cause the RNA molecule to be degraded. This interaction between the p16INK4a protein and the ANKRD65 molecule suggests that ANKRD65 may be a potential drug target for cancer.

Another potential drug target for ANKRD65 is the protein CSN5B, which is a component of the mitochondrial inner membrane. CSN5B has been shown to interact with the ANKRD65 molecule and can cause the RNA molecule to be translatable into protein. This interaction between the CSN5B protein and the ANKRD65 molecule suggests that ANKRD65 may be a potential drug target for diseases related to the mitochondria, such as cancer.

Potential Biomarkers

The ANKRD65 molecule has the potential to be used as a biomarker for various diseases. One of the potential applications of ANKRD65 is as a diagnostic biomarker for cancer. ANKRD65 has been shown to be expressed in various types of cancer, including breast, lung, and ovarian cancer. This suggests that ANKRD65 may be a useful biomarker for these types of cancer.

Another application of ANKRD65 is as a therapeutic biomarker. ANKRD65 has been shown to have anti-inflammatory effects and may be a potential therapeutic agent for diseases that are characterized by inflammation. For example, ANKRD65 has been shown to have anti-inflammatory effects in various types of diseases, including cancer and autoimmune diseases.

Conclusion

In conclusion, ANKRD65 is a unique and promising molecule that has the potential to be a drug target or biomarker for various diseases. The ANKRD65 molecule has been shown to interact with the protein p16INK4a and can cause the RNA molecule to be degraded. Additionally, ANKRD65 has been shown to have anti-inflammatory effects and may be a potential therapeutic agent for diseases characterized by inflammation. Further research is needed to fully understand the potential drug target and biomarker properties of ANKRD65.

Protein Name: Ankyrin Repeat Domain 65

The "ANKRD65 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANKRD65 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ANKRD65-AS1 | ANKRD66 | ANKRD7 | ANKRD9 | ANKS1A | ANKS1B | ANKS3 | ANKS4B | ANKS6 | ANKUB1 | ANKZF1 | ANLN | Annexin | ANO1 | ANO10 | ANO2 | ANO3 | ANO4 | ANO5 | ANO6 | ANO7 | ANO7L1 | ANO8 | ANO9 | Anoctamin | ANOS1 | ANOS2P | ANP32A | ANP32A-IT1 | ANP32AP1 | ANP32B | ANP32C | ANP32D | ANP32E | ANPEP | ANTKMT | ANTXR1 | ANTXR2 | ANTXRL | ANTXRLP1 | ANXA1 | ANXA10 | ANXA11 | ANXA13 | ANXA2 | ANXA2P1 | ANXA2P2 | ANXA2P3 | ANXA2R | ANXA2R-AS1 | ANXA2R-OT1 | ANXA3 | ANXA4 | ANXA5 | ANXA6 | ANXA7 | ANXA8 | ANXA8L1 | ANXA8L2 | ANXA9 | AOAH | AOC1 | AOC2 | AOC3 | AOC4P | AOPEP | AOX1 | AOX2P | AP-1 Transcription Factor Complex | AP1AR | AP1B1 | AP1B1P1 | AP1G1 | AP1G2 | AP1M1 | AP1M2 | AP1S1 | AP1S2 | AP1S3 | AP2A1 | AP2A2 | AP2B1 | AP2M1 | AP2S1 | AP3B1 | AP3B2 | AP3D1 | AP3M1 | AP3M2 | AP3S1 | AP3S2 | AP4B1 | AP4B1-AS1 | AP4E1 | AP4M1 | AP4S1 | AP5B1 | AP5M1 | AP5S1 | AP5Z1